R. Kaboo

发表

In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

R. Figlin, C. Tso, W. McBride, 1996, The Journal of clinical investigation.

Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.

A. Belldegrun, K. Michel, C. Tso, 1997, Cancer research.

Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients.

R. Figlin, C. Tso, M. Sokoloff, 1996, The Journal of urology.

The Use of Cytokines, Tumor Infiltrating Lymphocytes, and Gene Therapy in the Treatment of Advanced Renal Cell Carcinoma: The UCLA Experience

R. Figlin, A. Belldegrun, S. Taneja, 1995 .

Adenovirus‐Mediated Interleukin‐2 Production by Tumors Induces Growth of Cytotoxic Tumor‐Infiltrating Lymphocytes Against Human Renal Cell Carcinoma

R. Figlin, C. Tso, W. McBride, 1998, Journal of immunotherapy.

In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin‐2 and/or interferon‐alpha gene transfer

R. Figlin, A. Belldegrun, C. Sawyers, 1994, Cancer.

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

M. Roth, R. Figlin, C. Tso, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.

R. Figlin, A. Belldegrun, G. Steger, 1995, British Journal of Cancer.

Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo.

R. Figlin, A. Belldegrun, J. Czernin, 1994, Clinical immunology and immunopathology.

Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates.

M. Roth, K. Michel, C. Tso, 1998, Cancer research.

Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer.

C. Tso, M. Sokoloff, J. Dekernion, 1995, Human gene therapy.

Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

R. Figlin, A. Belldegrun, C. Tso, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Quantitative Polymerase Chain Reaction Does not Improve Preoperative Prostate Cancer Staging: A Clinicopathological Molecular Analysis of 121 Patients

R. Figlin, A. Belldegrun, C. Tso, 1998 .

Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.

A. Belldegrun, S. Barsky, C. Tso, 1993, Journal of the National Cancer Institute.

Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma

R. Figlin, A. Belldegrun, C. Tso, 1993 .

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

R. Figlin, A. Belldegrun, C. Tso, 1997, The Journal of urology.

Simultaneous use of two retroviral vectors in human gene marking trials: feasibility and potential applications.

C. Tso, W. McBride, A. Miller, 1992, Human gene therapy.

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.

R. Figlin, A. Belldegrun, C. Tso, 1993, The Journal of urology.

In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines

A. Belldegrun, S. Taneja, C. Tso, 1996, Cancer.